Image pharmaphorum Editor News Novel drug to tackle inflammatory diseases begins trial An early-stage drug that is being developed to tackle inflammatory and autoimmune diseases has been approved by the US regulator. News Lilly’s new drug Mounjaro (tirzepatide ) wins US FDA approva... Blood sugar control drug Mounjaro has been granted US regulatory approval, giving type 2 diabetics another way to help keep their glucose levels in check. Digital Pfizer: Pharma needs a business strategy for a digital world The unprecedented rate of digital acceleration seen in the first two years of COVID-19 has set in train an age of digital transformation. Partner Content Partner Content Content Factory 24/7: Viseven adds a Center of Excellence in... TALLINN, Estonia, May 11, 2022 – Viseven is proud to announce its latest venture - a brand new Center of Excellence in Jaipur, India. Load more results
News Novel drug to tackle inflammatory diseases begins trial An early-stage drug that is being developed to tackle inflammatory and autoimmune diseases has been approved by the US regulator.
News Lilly’s new drug Mounjaro (tirzepatide ) wins US FDA approva... Blood sugar control drug Mounjaro has been granted US regulatory approval, giving type 2 diabetics another way to help keep their glucose levels in check.
Digital Pfizer: Pharma needs a business strategy for a digital world The unprecedented rate of digital acceleration seen in the first two years of COVID-19 has set in train an age of digital transformation.
Partner Content Partner Content Content Factory 24/7: Viseven adds a Center of Excellence in... TALLINN, Estonia, May 11, 2022 – Viseven is proud to announce its latest venture - a brand new Center of Excellence in Jaipur, India.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
